Drugs – Generic
(MYL) Mylan Incorporated – Bull of the Day
Mylan, Inc. (MYL) is one of the leading players in the US generics market. The company holds immense potential as many blockbuster drugs have begun to go off-patent and many more will lose patent exclusivity in the next few years. Moreover, we are encouraged by Mylan’s...
30Jan2012 | vitalstocks | 0 comments | Continued(MYL) Mylan Earns FDA Approval
Generic maker, Mylan Inc. (MYL) recently announced that its Indian subsidiary Mylan Laboratories has received tentative approval from the US Food & Drug Administration (FDA) for a fixed-dose combination of generic versions of Bristol Myers Squibb’s (BMY) drug Reyataz and...
5Dec2011 | vitalstocks | 0 comments | Continued(MYL) Mylan Approved for Zinecard Generic
Mylan, Inc.’s (MYL) generic business was boosted further with the approval from the U.S. Food and Drug Administration (FDA) for its generic version of Pharmacia & Upjohn’s Zinecard injection. Zinecard injection, which is a chemoprotective agent, recorded revenue of...
1Dec2011 | vitalstocks | 0 comments | Continued(MYL) Mylan Settles with Novartis
Mylan, Inc. (MYL) recently announced a settlement agreement with Novartis (NVS) relating to the generic version of Novartis’ bioidentical estrogen therapy Vivelle-Dot. As a result of the resolution, the lawsuit filed by Novartis will be dismissed and Mylan can launch a generic...
28Nov2011 | vitalstocks | 0 comments | Continued(WPI) Watson Pharmaceuticals – Bull of the Day
Watson Pharmaceuticals, Inc. (WPI) posted second-quarter 2011 earnings of $1.01 per share, beating the Zacks Consensus Estimate by a penny and the year-ago earnings by $0.18 per share. Earnings were boosted by strong revenues, which jumped 24% to $1.08 billion, mainly driven...
31Oct2011 | vitalstocks | 0 comments | Continued(MYL) Mylan Settles with Roche for Xeloda
Mylan Inc. (MYL) recently announced that it has entered into a settlement and license agreement with Roche (RHHBY) bringing an end to its ongoing litigation with the latter relating to Roche’s cancer drug Xeloda. Mylan was looking to launch a generic version of the drug which...
23Sep2011 | vitalstocks | 0 comments | Continued(WPI) Watson Pharmaceuticals Analyst Maintains Outperform on Shares
We continue to have an Outperform recommendation on Watson Pharmaceuticals, Inc. (WPI), with a target price of $79.00, following the release of second quarter 2011 results. Watson Pharma’s second quarter earnings of $1.01 per share (excluding special items) outpaced the Zacks...
26Aug2011 | vitalstocks | 0 comments | Continued(MYL) Mylan Analyst Reaffirms Shares at Neutral
We have maintained our Neutral recommendation on Mylan Inc. (MYL) with a target price of $19.00 following an appraisal of second quarter 2011 financial results. Mylan’s second quarter 2011 earnings (excluding special items) of 52 cents per share were above the Zacks Consensus...
25Aug2011 | vitalstocks | 0 comments | Continued(MYL) Mylan and Endo Pharmaceuticals in Legal Tussle
Mylan Inc. (MYL) recently announced that Endo Pharmaceuticals (ENDP) filed a patent infringement lawsuit in connection with an abbreviated new drug application (ANDA) filed by Mylan with the US Food and Drug Administration (FDA) for the generic version of Endo’s acute migraine...
18Aug2011 | vitalstocks | 0 comments | Continued(MYL) Mylan Beats Second Quarter Earnings on All Fronts
Mylan Inc.’s (MYL) second quarter 2011 earnings (excluding special items) of 52 cents per share were above the Zacks Consensus Estimate of 45 cents as well as the year-ago earnings of 37 cents per share. Earnings growth was driven by increase in generics revenue and improved...
27Jul2011 | vitalstocks | 0 comments | Continued(WPI) Watson Pharmaceuticals – Bull of the Day
Based on its first quarter performance and increased guidance, we are upgrading Watson Pharmaceuticals (WPI) to Outperform. The company posted first-quarter 2011 earnings of $0.89 per share, beating the Zacks Consensus Estimate by $0.03 and the year-ago earnings by $0.08 per...
14Jul2011 | vitalstocks | 0 comments | Continued(MYL) Mylan Gets HIV Rights from Gilead
Mylan, Inc. (MYL) recently announced that its Indian subsidiary Matrix Laboratories has been granted future rights to produce and sell generic versions of three investigational HIV therapies of Gilead Sciences, Inc. (GILD), if and when approved. The agreement aims to expand access...
14Jul2011 | vitalstocks | 0 comments | Continued(WPI) Watson Pharmaceuticals Entangled in Legal Dispute
The legal tussle between Watson Pharmaceuticals Inc. (WPI) and Shire plc (SHPGY) intensified, with the latter filing a patent infringement case against Watson Pharma relating to Vyvanse. Vyvanse is indicated for the treatment of attention deficit hyperactivity disorder (ADHD)...
8Jul2011 | vitalstocks | 0 comments | Continued(PRX) Par Pharmaceutical Restructures Branded Business
Par Pharmaceutical Companies, Inc. (PRX) is in for a strategic assessment as it announced restructuring plans for its branded drugs segment, Strativa Pharmaceuticals. The company will reduce its workforce by about 100 people as a result of the restructuring, which is expected...
5Jul2011 | vitalstocks | 0 comments | Continued(WPI) Watson Pharmaceuticals and Columbia Laboratories Drug’s NDA Accepted
Watson Pharmaceuticals Inc. (WPI) along with Columbia Laboratories Inc. (CBRX) recently announced that the latter’s New Drug Application (NDA) for Prochieve (progesterone gel) has been accepted by the US Food and Drug Administration (FDA). The companies are looking to get Prochieve...
29Jun2011 | vitalstocks | 0 comments | Continued(WPI) Watson Pharmaceuticals Files More Abbreviated New Drug Applications
Watson Pharmaceuticals Inc. (WPI) recently announced that it has filed Abbreviated New Drug Applications (ANDA) with the US Food and Drug Administration (FDA) to market its generic version of GlaxoSmithKline plc’s (GSK) Avodart, indicated for the treatment of benign prostatic...
29Jun2011 | vitalstocks | 0 comments | Continued(MYL) Trial Date for Teva Pharmaceuticals / Mylan Dispute
Mylan Inc. (MYL) received some good news recently when a US District court denied Teva Pharmaceuticals Industries’ (TEVA) motion for a summary judgment, finding no inequitable conduct in the Copaxone infringement lawsuit. The court has ordered that the trial for inequitable...
22Jun2011 | vitalstocks | 0 comments | Continued(WPI) Watson Pharmaceuticals Wins Favorable Ruling Against Teva Pharmaceutical Industries
Watson Pharmaceuticals Inc. (WPI) recently announced that the United States District Court for the District of Nevada denied Teva Pharmaceutical Industries Ltd.’s (TEVA) request for a preliminary injunction and a temporary restraining order to prevent Watson Pharma from launching...
21Jun2011 | vitalstocks | 0 comments | Continued(WPI) Watson Pharmaceuticals Seeks Generic Viagra Approval
Watson Pharmaceuticals Inc. (WPI) recently announced that it has filed an Abbreviated New Drug Application (ANDA) with the US Food and Drug Administration (FDA) to market its generic version of Pfizer Inc.’s (PFE) erectile dysfunction (ED) drug, Viagra sildenafil citrate tablets. In...
16Jun2011 | vitalstocks | 0 comments | Continued(MYL) Mylan Launches New Generic Pharmaceuticals
Mylan Inc.’s (MYL) generic portfolio continued to be boosted with the launch of the generic version of Xanodyne Pharmaceutical’s pain reliever Roxicodone. The generic has been launched under a development and supply agreement with Coastal Pharmaceuticals. The product recorded...
27May2011 | vitalstocks | 0 comments | Continued(MYL) Mylan Launches Generic Drugs
MylanInc. (MYL) recently launched its generic version of Ista Pharmaceuticals Inc’s (ISTA) Xibrom ophthalmic solution, used for the treatment of inflammation in patients who have undergone a cataract extraction operation. The generic has been launched under a development and...
21May2011 | vitalstocks | 0 comments | Continued(WPI) Watson Pharmaceuticals Beats on Earnings – Increases Guidance
Watson Pharmaceuticals Inc.‘s (WPI) first quarter 2011 earnings (excluding special items) of 89 cents per share beat the Zacks Consensus Estimate by 3 cents and the year-ago earnings by 8 cents. Earnings were bolstered by higher revenues and reduced cost, resulting from...
3May2011 | vitalstocks | 0 comments | Continued(MYL) Mylan Meets Analyst Estimates – Sales Upbeat
Mylan Inc.’s (MYL) first quarter 2011 earnings (excluding special items) of 44 cents per share were in line with the Zacks Consensus Estimate. A higher quarterly tax rate, increased share count and pricing pressure in Europe offset the increase in generics revenue in North...
3May2011 | vitalstocks | 0 comments | Continued(MYL) Mylan Analyst Maintains Neutral Rating on Shares
We have maintained our Neutral recommendation on Mylan Inc. (MYL) with a target price of $23.00 after appraising fourth quarter and fiscal year 2010 financial results. Mylan’s fourth quarter 2010 earnings (excluding special items) of 45 cents per share were at par with the...
20Mar2011 | vitalstocks | 0 comments | Continued(WPI) Watson Pharmaceuticals Analyst Maintains Neutral Rating on Shares
We recently reaffirmed our Neutral stance on Watson Pharmaceuticals Inc. (WPI) following the release of fourth quarter and fiscal year 2010 financial results. Quarterly earnings of 93 cents per share were in line with the Zacks Consensus Estimate and 8 cents above the year-ago...
17Mar2011 | vitalstocks | 0 comments | Continued(WPI) Watson Pharmaceuticals Quarterly Earnings Report Outperforms Expectations
Watson Pharmaceuticals Inc.‘s (WPI) fourth quarter 2010 earnings (excluding special items) of $0.93 per share were in line with the Zacks Consensus Estimate and $0.08 above the year-ago earnings. Earnings, however, dropped 70.6% to $0.15 per share on a reported basis...
16Feb2011 | vitalstocks | 0 comments | Continued(MYL) Mylan Earns FDA Approval for Generic Version of Valtrex
Recently, Mylan Inc. (MYL) received approval from the US Food and Drug Administration (FDA) for its generic version of GlaxoSmithKline’s (GSK) Valtrex, a treatment for herpes virus infection. The drug recorded US sales of about $2.15 billion in 2009 for the twelve months ending...
30May2010 | vitalstocks | 0 comments | Continued(MYL) Mylan First Quarter 2010 Earnings Scorecard
First Quarter Highlights On April 29, Mylan (MYL) reported first quarter fiscal 2010 earnings per share (EPS) of 20 cents, down from the year-ago earnings of 23 cents. On an adjusted basis, first quarter earnings came in at 36 cents, a couple of cents above the Zacks Consensus...
24May2010 | vitalstocks | 0 comments | Continued(WPI) Watson Pharmaceuticals Demonstrates Growth in Generic Drugs
Financial Tides likes Watson Pharmaceuticals, Inc. (WPI) a pharmaceutical company primarily engaged in the development, production, marketing and distribution of both branded and off-patent pharmaceutical products. The company’s branded pharmaceutical business operates...
20May2010 | Shawn | 0 comments | Continued(MYL) Mylan’s Quarterly Earnings Tops Expectations
Mylan (MYL) reported first quarter earnings per share of 20 cents, down from the year-ago earnings of 23 cents. On an adjusted basis, first quarter 2010 earnings came in at 36 cents, a couple of cents above the Zacks Consensus Estimate and well above the year-ago earnings of...
29Apr2010 | vitalstocks | 0 comments | Continued